Selective histone deacetylase inhibitors for the treatment of human disease
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.
1. A compound comprising the formula (Ia) or (Ib)
wherein R 1 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 2 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 3 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
X is a substituent selected from the group consisting of —N(R 4 )C(O)—, —C(O)N(R 4 )—, —S(O) 2 N(R 4 )—, —N(R 4 )S(O) 2 —,
where R 4 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl; n is an integer from 5 to 7; or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
2. The compound of claim 1 comprising the formula (II):
wherein R 11 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 12 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 13 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl; or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
3. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
4. The compound of claim 1 , comprising the formula (III):
wherein R 21 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 22 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl;
R 23 is a substituent selected from the group consisting of H and optionally substituted alkyl and aryl; or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
5. The compound of claim 4 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
6. The compound of claim 1 , wherein the compound is a selective HDAC6 inhibitor.